When the Trial Ends: The Case for Post-Trial Provisions in Clinical Psychedelic Research

E. and colleagues interpret the ethical and practical implications of psychedelic-assisted psychotherapy through three atypical features of such trials. First, unlike most investigational drugs, psychedelics (notably psilocybin) are often accessible outside formal trials—either in extralegal domestic markets or legally in other jurisdictions—creating pressure on former participants to seek further treatment "in the wild." The authors note empirical signals from trials that some participants do attempt to obtain psychedelics after trial completion (at least three of 20 participants in one Imperial College pilot reported doing so), and they highlight the legal, safety, and equity risks posed by underground or unregulated retreat settings. Second, the authors argue that the short, time-limited structure of many psychedelic trials can mean the protocol-defined endpoint comes too early to conclude the broader therapeutic process safely for some participants. Psychedelic dosing sessions are embedded in preparatory and integrative psychotherapy, and for some individuals the integration process may continue or unfold well beyond the trial's end. The text describes empirical indicators relevant to this concern: psilocybin trials commonly employ one to three high-dose sessions (c. 20–35 mg), many trials follow with a variable number of integration sessions, and in one open-label Imperial trial some participants who were treatment responders (defined as at least a 50% reduction in depression severity at one week) relapsed by six months (one-third of responders). The authors also cite meta-analytic and epidemiological evidence suggesting multiple dosing sessions may be associated with greater symptom relief and that repeated psychedelic use has not been linked to increased adverse outcomes in large surveys—evidence they say can be cautiously drawn upon when considering post-trial access. Third, the paper emphasises the unusual depth and intensity of the researcher-therapist/participant relationship in psychedelic trials. Preparation phases and long dosing days (sometimes up to eight hours) foster strong therapeutic rapport; the authors refer to the partial-entrustment model to argue that such depth of relationship, together with participant vulnerability and lack of alternative providers, increases researchers' ancillary care obligations. They report that some researcher-therapists already provide low-cost or pro bono integration groups, but regard relying on such goodwill as unsustainable and unjust. On that basis, the authors propose reconceptualising PTA as a broader post-trial care framework. Recommended components include, depending on clinical need: additional drug-assisted sessions where appropriate, non-drug psychotherapy or integration counselling, psychoeducation and harm-reduction resources, researcher-affiliated community or peer-support initiatives, and systematic data collection on post-trial interventions to inform safety and effectiveness. They advise transparent pre-registration and reporting of any post-trial provisions so that scientific integrity is preserved and additional "real-world" evidence can be generated. The authors discuss stakeholder responsibilities. For governments, they suggest legal reforms (for example, rescheduling or decriminalisation measures) could reduce criminal and bureaucratic barriers that currently impede safe post-trial access and increase costs. Investigator teams are encouraged to incorporate harm-reduction guidance and standardised post-trial contingencies into protocols to reduce the ethical double-bind experienced by researcher-therapists. Research sponsors are invited to view post-trial care as a futureproofing investment that will build infrastructure and generate knowledge useful for later clinical roll-out. Institutional Review Boards might also request substantive plans for post-trial care. The authors acknowledge alternative cost-sharing mechanisms (co-payments, sliding scales) have precedent in other contexts. E. and colleagues acknowledge significant practical constraints and counterarguments. They recognise the distinction between research and healthcare, and that some funders (for example, certain national research agencies) are not authorised to pay for routine clinical services. They also concede that expanding post-trial provisions will increase trial costs and could, in some cases, make studies less economically viable. Nonetheless, they argue that planning post-trial care as part of research—accompanied by monitoring and outcome reporting—can produce data that benefits sponsors and the broader field. They call for further work to define thresholds and principled criteria (e.g. severity, treatment resistance, number of prior failed interventions) for when different forms of post-trial support should be provided, emphasising that responsibility should be distributed across researchers, sponsors, and host governments rather than falling on individual practitioner goodwill. Key limitations and uncertainties they acknowledge include the currently incomplete evidence base on risks and benefits of repeated psychedelic dosing, the heterogeneity of participant needs across indications, the resource intensity of proposed provisions, and legal/regulatory barriers that complicate implementation. The authors present their proposals as initial, pragmatic steps—ranging from low-cost psychoeducation and peer support to more resource-intensive options such as funded integration therapy or additional drug sessions—intended both to meet present ethical obligations and to support the development of the infrastructure required for a mainstream psychedelic medicine ecosystem.